Fortis Healthcare has announced its audited financial results for the quarter and year ended March 31, 2026, showing strong growth. For FY26, the company achieved a consolidated revenue of INR 9,128 crore, a 17.3% increase, and a 31.5% rise in profit after tax to INR 1,064 crore. The Board of Directors has recommended a dividend of INR 1 per share, representing 10% of the face value.
Robust Annual Financial Performance
Fortis Healthcare demonstrated significant operational progress throughout FY26. Consolidated revenue reached INR 9,128 crore, reflecting a 17.3% year-on-year growth. Operating EBITDA for the year climbed by 31.3% to reach INR 2,085 crore, with margins expanding to 22.8% from 20.4% in the previous year. Profit after tax for the year stood at INR 1,064 crore, marking a 31.5% increase compared to FY25.
Q4 FY26 Highlights
The final quarter of the fiscal year maintained this upward momentum. Q4 FY26 consolidated revenues rose 17.8% to INR 2,365 crore compared to the same period in the previous year. Operating EBITDA grew by 22.2%, achieving a margin of 22.5%. Profit after tax for the quarter reached INR 271 crore, a 44.2% improvement over Q4 FY25.
Hospital and Diagnostics Business Expansion
The hospital segment remains a primary growth driver, contributing 85% to total revenues. Performance was bolstered by a 15% increase in occupied beds over the fiscal year. Key procedure volumes also surged, with robotic surgeries rising by 66% and radiation therapy growing by 19%. The company’s inorganic growth strategy was highlighted by the acquisition of People Tree Hospital in Bengaluru and Shrimann Hospital in Jalandhar, adding approximately 500 beds to its network.
The diagnostics business, operating under Agilus, recorded gross revenues of INR 1,527 crore for FY26, an 8.5% growth. The division successfully expanded its network by adding 675+ new customer touchpoints, bringing the total to 4,445 by the end of the year.
Strategic Outlook and Capital Allocation
Fortis continues to focus on augmenting its medical infrastructure, commissioning high-end equipment including five soft tissue surgical robots and various MRI and Cath labs during the year. The company’s net debt stood at INR 2,334 crore, with a net debt to EBITDA ratio of 1.09x. Reflecting the company’s strong financial health and confidence, the Board has recommended a dividend of INR 1 per share.
Source: BSE
